Cargando…

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy

BACKGROUND: The majority of anal cancers (84–95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Alexandra K, Kartsonaki, Christiana, Collantes, Elena, Nicholson, Judith, Gilbert, Duncan C, Kiltie, Anne E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537498/
https://www.ncbi.nlm.nih.gov/pubmed/28641314
http://dx.doi.org/10.1038/bjc.2017.188
Descripción
Sumario:BACKGROUND: The majority of anal cancers (84–95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers. METHODS: Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease. RESULTS: We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy. CONCLUSIONS: MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.